(Q46757816)

24 December 2017

title

Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas (English)

1 reference

24 December 2017

1 reference

Wei-Shuai Liu

1

1 reference

24 December 2017

Lu-Jun Zhao

2

1 reference

24 December 2017

Qing-Song Pang

3

1 reference

24 December 2017

Zhi-Yong Yuan

4

1 reference

24 December 2017

Bo Li

5

1 reference

24 December 2017

Ping Wang

6

1 reference

24 December 2017

publication date

19 November 2013

1 reference

24 December 2017

published in

Medical Oncology

1 reference

24 December 2017

volume

31

1 reference

24 December 2017

issue

1

1 reference

24 December 2017

page(s)

771

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1007/s12032-013-0771-9

exact match

0 references

cites work

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

Unraveling the mystery of prognostic and predictive factors in epidermal growth factor receptor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

EGFR and erbB2 mutation status in Japanese lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

Non-BAC Component but not Epidermal Growth Factor Receptor Gene Mutation is Associated with Poor Outcomes in Small Adenocarcinoma of the Lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0771-9

Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer

21 January 2018

1 reference

12 December 2020

Clinical investigation of EGFR mutation detection by pyrosequencing in lung cancer patients

1 reference

12 December 2020

[Treatment and prognostic analysis of 1638 patients with non-small cell lung cancer]

1 reference

12 December 2020

A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.

1 reference

12 December 2020

10.1007/S12032-013-0771-9

Identifiers

DOI

1 reference

24 December 2017

1 reference

24 December 2017